New target for Oncoceutics' GPCR-targeting compounds
Oncoceutics' compounds increase mitochondrial protease activity to kill cancer
Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease.
Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including dopamine receptors. Oncoceutics’ management team told BioCentury its lead product,